Skip to main content
Top
Published in: Indian Journal of Pediatrics 2/2017

01-02-2017 | Scientific Letter

Ventricular Tachycardia: A Rare Side Effect of Voriconazole

Authors: Pooja Dewan, Sunil Gomber, Vanny Arora

Published in: Indian Journal of Pediatrics | Issue 2/2017

Login to get access

Excerpt

To the Editor: An 11-y-old boy being treated for aplastic anemia developed fever with hematuria on 15th day of cyclosporine therapy. Investigations revealed: hemoglobin 7g/dL, total leucocyte count 2300/mm3 and platelet count 20,000/mm3. The child was started on intravenous ceftazidime and amikacin and supportive therapy. However after 48h, his fever persisted and antibiotics were changed to intravenous vancomycin and meropenem. A day later, the child developed extensive oral thrush with palatal ulcerations and amphoterecin B was also started. Three days later, oral lesions improved but the blood urea increased to 65mg/dL. Intravenous amphoterecin B and vancomycin were substituted with intravenous voriconazole and teicoplanin. On 16th day of voriconazole therapy, he complained of transient visual disturbances lasting for about 5 min. The ocular examination was found unremarkable. On 20th day of voriconazole therapy, he developed mild jaundice and investigations revealed serum bilirubin 3mg/dL, serum glutamic pyruvate transaminase 80IU/dL, and serum glutamic ornithine transaminase 76IU/dL. In view of hepatitis, voriconazole therapy was interrupted while intravenous antibiotics were continued. A week later, the liver functions normalized, but fever and oral lesions re-appeared. The child was re-started on intravenous voriconazole. The blood and urine cultures were sterile. Chest radiograph and ultrasonogram of chest were unremarkable. Two days later, the child complained of decreased oral acceptance and dizziness. Examination revealed heart rate (HR) 160/min, respiratory rate (RR) 26/min, and blood pressure 75/50 mmHg. The child was administered intravenous fluid bolus and dopamine infusion was started. Investigations revealed: hemoglobin 6g/dL, total leucocyte count 1100/mm3, platelet count 10,000/mm3, blood urea 49mg/dL, serum sodium 135mEq/L, serum potassium 4.2mEq/L and serum calcium 9mg/dL. Electrocardiogram revealed monomorphic ventricular tachycardia (Fig. 1). In view of hypotension and ventricular tachycardia, direct-current (DC) cardioversion was attempted but the child succumbed.
Literature
1.
go back to reference Lehrnbecher T, Phillips R, Alexander S, et al; International Pediatric Fever and Neutropenia Guideline Panel. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427–38. Lehrnbecher T, Phillips R, Alexander S, et al; International Pediatric Fever and Neutropenia Guideline Panel. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427–38.
2.
3.
go back to reference Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240–8.CrossRefPubMed Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240–8.CrossRefPubMed
4.
go back to reference Neely M, Rushing T, Koovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27–36.CrossRefPubMedPubMedCentral Neely M, Rushing T, Koovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27–36.CrossRefPubMedPubMedCentral
5.
go back to reference Uludağ D, Ozdemir N, Tüysüz G, Eroğlu AG, Celkan T. Voriconazole induced bradycardia. Pediatr Hematol Oncol. 2013;30:674–6.CrossRefPubMed Uludağ D, Ozdemir N, Tüysüz G, Eroğlu AG, Celkan T. Voriconazole induced bradycardia. Pediatr Hematol Oncol. 2013;30:674–6.CrossRefPubMed
6.
go back to reference Perbet S, Blondonnet R, Guérin R, Cayot-Constantin S, Constantin JM. Voriconazole-induced bradycardia without QT interval prolongation: a possible non-concentration-dependent adverse effect. Intensive Care Med. 2013;39:531–2.CrossRefPubMed Perbet S, Blondonnet R, Guérin R, Cayot-Constantin S, Constantin JM. Voriconazole-induced bradycardia without QT interval prolongation: a possible non-concentration-dependent adverse effect. Intensive Care Med. 2013;39:531–2.CrossRefPubMed
7.
go back to reference Zeuli JD, Wilson JW, Estes LL. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob Agents Chemother. 2013;57:1121–7.CrossRefPubMedPubMedCentral Zeuli JD, Wilson JW, Estes LL. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob Agents Chemother. 2013;57:1121–7.CrossRefPubMedPubMedCentral
8.
go back to reference De Ponti F, Polluzi E, Cavelli A, Recanatini M, Montanaro N. Safety of non-arrhythmogenic drugs that prolong the QT interval or induce torsedo de pointis. Drug Saf. 2002;25:263–86.CrossRefPubMed De Ponti F, Polluzi E, Cavelli A, Recanatini M, Montanaro N. Safety of non-arrhythmogenic drugs that prolong the QT interval or induce torsedo de pointis. Drug Saf. 2002;25:263–86.CrossRefPubMed
Metadata
Title
Ventricular Tachycardia: A Rare Side Effect of Voriconazole
Authors
Pooja Dewan
Sunil Gomber
Vanny Arora
Publication date
01-02-2017
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 2/2017
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-016-2217-9

Other articles of this Issue 2/2017

Indian Journal of Pediatrics 2/2017 Go to the issue